vTv Therapeutics Inc (VTVT)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$33.35-0.36%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · VTVT
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Worth watching into the next print: this name has erratic recent earnings surprises and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
VTVT — earnings miss
Dated 2026-08-06
Results of Operations and Financial Condition On August 6, 2026, vTv Therapeutics Inc. issued a press release to announce its financial results for the fiscal period ended June 30, 2026. A copy of the press release is attached as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference. The information in this report (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18, of the Securities Exchange Act of 1934, as amended (the “Exc…
Why it matters: Monitoring cash burn is crucial as the company funds its operations through the CATT1 trial. A high burn rate could raise concerns about financial stability.
Worry ifCash burn rate in Q2 2026 is less than $10 million.
Less concerning ifCash burn rate exceeds $15 million in Q2 2026.
Why it matters: Higher net income means better efficiency. This can make investors more confident.
Supportive ifNet income improves to at least $30M in Q2.
Worry ifNet income drops below $20M in Q2.
Why it matters: Updates may bring in more money without giving up shares. This helps with running the business and growing it.
Supportive ifLook for news about more milestone payments or royalties from the Newsoara deal.
Worry ifNo new updates or payments from the Newsoara deal.
Why it matters: Cash updates will show if vTv can fund operations through key milestones. It's vital for stability.
Watch forCash position remains above $80 million through Q4 2026.
Also watch forCash position falls below $80 million before Q4 2026.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$218 on $10,000 · ±2.2% | How much price usually moves either way. |
| Bad day | $690 loss on $10,000 · 6.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,206 loss on $10,000 · 32.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Updates on cash will show if vTv can keep running until the CATT1 data readout.
Worry ifCash and cash equivalents remain above $80 million through the CATT1 data readout.
Less concerning ifCash and cash equivalents fall below $80 million before the CATT1 data readout.
Why it matters: Exceeding this revenue would show strong momentum from partnerships. It confirms management's growth strategy.
Supportive ifQ2 revenue was over $36.839M. This shows growth from partnerships.
Worry ifQ2 revenue was under $36.839M. This suggests slower growth from partnerships.
Why it matters: Continued revenue growth signals the success of strategic partnerships. This can attract more investors.
Supportive ifQ2 revenue growth exceeds 10% year over year.
Worry ifQ2 revenue growth falls below 5% year over year.
Why it matters: Earnings reports show how well the company is doing. Investors will pay attention to these results.
Watch forEarnings report shows strong performance metrics.
Also watch forThe earnings report shows poor results.
Why it matters: If health care sector revenue growth speeds up, it could boost vTv's performance and investor sentiment.
Supportive ifHealth care sector revenue growth rises back toward 10% or higher.
Worry ifSector revenue growth is slowing down. It is now below 8%.
Why it matters: The KOL event will highlight cadisegliatin's potential in T1D. It could influence investor interest.
Watch forThe KOL event occurs. Experts give positive feedback on cadisegliatin.
Also watch forThe KOL event occurs but receives negative or mixed feedback from experts.
Why it matters: Updates on the ATM program can indicate how well the company is raising capital. This affects future growth.
Watch forThey announced they raised over $10M through the ATM program.
Also watch forThere will be no major updates or money raised through the ATM program next quarter.
Why it matters: Earnings results will show if revenue keeps growing. They will also show if operations get better.
Watch forQ2 2026 revenue exceeds $36.839 million, showing continued growth.
Also watch forIf Q2 2026 revenue is less than $36.839 million, it may mean problems.
Why it matters: Finishing enrollment is important for cadisegliatin's growth. It shows we are making progress.
Supportive ifEnrollment in the Phase 3 CATT1 trial is completed by the end of Q3 2026.
Worry ifEnrollment is not completed by the end of Q3 2026.
Why it matters: New partnerships could help grow revenue and support the company's long-term plans. This matches management's goal to increase revenue.
Supportive ifA new strategic partnership has been announced that helps grow revenue.
Worry ifNo new partnerships announced, and revenue growth stagnates.
Why it matters: Starting this trial is key for testing cadisegliatin in a new treatment approach for type 1 diabetes.
Supportive ifThe Phase 2a Hybrid CATT1 trial begins before the end of 2026.
Worry ifThe trial is not initiated by the end of 2026.
Why it matters: The KOL event may give clues about cadisegliatin's potential. It could boost investor confidence.
Supportive ifThe KOL event is successfully hosted in Q4 2026 with positive feedback.
Worry ifThe KOL event is canceled or poorly received.